Citations

Clear

1792 citation(s) found for "Stephanie".

Clinical Recommendations for Remote Robotic Assisted Surgery From the CRSA 2025 International Consensus Conference
Raptis, Dimitri Aristotle , Kavoussi, Louis, Wren, Sherry M. , Fowler, Dennis, Anvari, Mehran, Bianco, Francesco, Liang, Xiao, Li, Zheyong, Yin, Xiaoyu, Piccoli, Micaela, Marks, John, Shen, Baiyong, Ko, Clifford, Seeliger, Barbara, Hagendoorn, Jeroen, Essani, Rahila, Walsh, R. Matthew, Oleynikov, Dmitry, Jones, Stephanie B., Bindal, Vivek , Kim, Hyun Koo, Hyung, Woo Jin, Hashimoto, Daniel, Chen, Liaohai Leo, Burt, Bryan M., Lafaro, Kelly, Elli, Fernando, Wilson, Erik, Bianchi, Paolo Pietro, Morgan, Annette, Bartlett, Stephen T., Rashidi, Laila, Yu, Liu, Gawkins, Bill, Hinoul, Piet, Peine, Bill, Woo, Yanghee, Raoof, Mustafa, Jones, Daniel, Deshpande, Supriya, Bernard, Jordana , Wang, Yulun, Broering, Dieter C., Giulianotti, Pier Cristoforo, Fong, Yuman , Raptis, Dimitri , Wren, Sherry M , Aldousari, Saad , Ruurda, Jelle P. H. , Bindal, Vivek , Melstrom, Laleh , Celotto, Francesco , Kudsi, Yusef , Ratti, Francesca , Bernard, Jordana , Kavoussi, Louis R., Fowler, Dennis L. , Anvari, Mehran , Bianco, Francesco Maria , Piccoli, Micaela , Marks, John, Ko, Clifford, Seeliger, Barbara , Hagendoorn, Jeroen , Essani, Rahila, Walsh, R. Matthew , Oleynikov, Dmitry , Hyung, Woo Jin , Hashimoto, Daniel A. , Burt, Bryan M. , Lafaro, Kelly J. , Elli, Fernando, Bianchi, Paolo Pietro, Rashidi, Laila, Hinoul, Piet , Peine, Bill, Woo, Yanghee , Raoof, Mustafa , Jones, Daniel, Deshpande, Supriya , Bröering, Dieter C. , Giulianotti, Pier Cristoforo

Mayo Clinic

World Journal of Surgery | July 14, 2026 | Volume: 50 | Issue: 8 | Pages: 2274-2288

10.1002/wjs.70468 | PMID 42444290 Get It

ABSTRACT Background Implementation of remote robotic‐assisted surgery (rRAS) has the potential to significantly improve access to high‐quality surgical care for patients worldwide. Advances in robotic systems and telecommunications now enable highly reliable, low latency, and cybersecure connectivity. These technological developments, together with the broader adoption of telemedicine, have driven an increasing interest in the implementation of rRAS. Methods The Clinical Robotic Surgery Association (CRSA) convened a conference to develop international clinical recommendations for rRAS using the Danish Model of Consensus. The society identified five key issue categories and invited a panel of experts to address specific questions for each. Panel members and a jury of 10 unbiased, non‐expert in rRAS professionals participated in a day‐long conference on November 19, 2025 (Los Angeles, USA). During the conference, participants presented, discussed, and reached consensus on specific guidelines relevant to each category. Immediately after the conference, the jury reviewed and approved the recommended guidelines. Results Multiple recommendations were approved for each of the following categories: Operating Models, Roles and Responsibilities (2 recommendations), Clinical Pathway (2 recommendations), Emergency Management (8 recommendations), Technical Considerations (5 recommendations), and Medico‐legal and Ethical Considerations (4 recommendations). Conclusions There was consensus that with recent advances in telecommunication and robotic technologies, rRAS can be offered safely and effectively if the identified safeguards are realized. Adoption of rRAS is expected to continue advancing rapidly.
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease
Soleimani‐Meigooni, David N. , Chiotis, Konstantinos, Allen, Isabel E., Rabinovici, Gil D., Joie, Renaud La , Group, Meta-Centiloid Study, Apostolova, Liana G. , Asken, Breton M., Benzinger, Th., Betthauser, Tobey J., Bluma, Marina, Bombois, Stephanie, Bourgeat, Pierrick, Bouteloup, Vincent , Braskie, Meredith N., Brendel, Matthias, Brickman, Adam M., Bryant, Natalie, Bullich, Santiago , Carrillo, Maria C., Casaletto, Kaitlin, Cash, David M., Chang, Chiung-Chih, CHANG, H L, Chao, Yishu , Collij, Lyduine E., Corrada, Maria M., Craft, Suzanne , Dickerson, Bradford C., Dubois, Bruno, Dufouil, Carole, Fajardo, Alfonso, Farrar, Gill , Fortea, Juan, Frings, Lars , Frisoni, Giovanni B., Gardner, Raquel C., Gnörich, Johannes , Gordon, Brian A., Gu, Yuna , Guan, Yihui, Guo, Tengfei, Hanseeuw, Bernard J., Hansson, Oskar, Harrison, Theresa M., Huang, Qi, Huang, ST , Iaccarino, Leonardo, Ishii, Kazunari, Ishi, Kenji, Jagust, William J., Johnson, Sterling C., Kato, Takashi, Katsumi, Yuta, Kaye, Jeffrey, Kolinger, Guilherme D., Kramer, Joel H. , Landau, Susan M., Landeau, Brigitte, Lao, Patrick J., Lee, Sangwon, Lopresti, Brian J., Lowe, Val J. , Luchsinger, José A., Mao, Xiaoxie, March, Andrew, Masters, Colin L., Meyer, Philipp T., Mezenge, Florence, Mormino, Elizabeth C., Franquesa‐Mullerat, María , Nakamura, Akinori, Nordberg, Agneta, O’Brien, John T., O’Bryant, Sid E., Pappas, Ioannis, Peretti, Debora E., Rowe, Christopher C., Rowe, James B., Schwartz, Daniel L., Seo, Sang Won , Shekari, Mahnaz, Smith, Ruben, Snyder, Heather M. , Sokolowski, Andrzej, Sperling, Reisa A., Sun, Pan, Taggett, Jacinda Z., Touroutoglou, Alexandra , Vaillancourt, David E., Giessen, Elsmarieke van de, Vijverberg, Jort, Villemagne, Victor L. , Villeneuve, Sylvia , Wang, Wei-en, Weiner, Michael, Woodworth, Davis, Xiao, Cally , Xie, F, Yoon, Yeojun, Yun, Mijin, Severanc, A4, ABIDE, ADNI*, ADNI-DoD, AgeWell, AIBL, AMYPAD, BACS, BATON, BIOCARD, BLSA, BioFINDER-2, BrANCH, CPAS, DETECT-AD, GEMS, GHABS, HABS, HABS-HD, IDEAS, IMAP, INSIGHT-preAD, Insight46, K-ROAD, LEADS, MCSA, MULNIAD, MEMENTO, SCAN, PREVENT-AD, SPIN,, Corrada, María M. , La Joie, Renaud , Blazhenets, Ganna , Chiotis, Konstantinos , Allen, Isabel Elaine , Rabinovici, Gil D. , Asken, Breton M. , Bejanin, Alexandre , Benzinger, Tammie L.S. , Betthauser, Tobey J. , Blūma, Marina , Bombois, Stéphanie , Bourgeat, Pierrick , Braskie, Meredith N. , Brendel, Matthias , Brickman, Adam M. , Carrillo, María C. , Casaletto, Kaitlin B. , Cash, David M. , Chang, Chiung‐Chih , Chang, Hsin‐I , Chêne, Geneviève , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Bradford Clark , Dubois, Bruno , Dufouil, Carole , Fortea, Juan , Garibotto, Valentina , Gordon, Brian A. , Guan, Yihui , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Iaccarino, Leonardo , Ishii, Kazunari , Ishii, Kenji, Jagust, William J. , Johnson, Sterling C. , Katsumi, Yuta , Kaye, Jeffrey , Koeppe, Robert A. , Kolinger, Guilherme Domingues , Landau, Susan , Landeau, Brigitte , Lao, Patrick , Lee, Sangwon, Lleó, Alberto , Lopresti, Brian J. , Malpetti, Maura , March, Andrew, Masters, Colin L. , Mézenge, Florence, Mormino, Elizabeth C. , Nakamura, Akinori , Nordberg, Agneta , O'Brien, John Tiernan , O’Bryant, Sid E. , Pappas, Ioannis , Quenon, Lisa , Rowe, Christopher Cleon , Rowe, James B. , Rudolph, Marc D. , Salvadó, Gemma , Schott, Jonathan M. , Schwarz, Christopher G. , Shekari, Mahnaz , Silbert, Lisa C. , Smith, Ruben, Sokolowski, Andrzej, Sperling, Reisa Anne , Sun, Pan , Taggett, Jacinda , Toga, Arthur W. , Vaillancourt, David E. , Giessen, Elsmarieke van de , Vemuri, Prashanthi , Villain, Nicolas , Wang, Wei‐en , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Yun, M R

Mayo Clinic

JAMA | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.13116 | PMID 42441390 Get It

Importance Amyloid positron emission tomography (PET) is increasingly used in research and clinical settings to determine the etiology of cognitive decline and eligibility for amyloid-targeting therapies. To assist with amyloid PET evaluation and to guide clinical decision-making, images can be quantified in a standardized unit called Centiloid, the interpretation of which can vary according to the method and threshold used. Objective To collect Centiloid values from available studies and determine robust positivity cutoffs using data-driven methods and correspondence with visual reads. Data Sources PubMed search (October 2024) identified studies with Centiloid values. Corresponding authors were invited to share individual participant data. Additional data were obtained through access-controlled repositories and conference outreach (July 2024-July 2025). Study Selection Studies were included if they provided Centiloids, radiotracer, age, and sex. Data Extraction and Synthesis Each study was analyzed using a unified statistical pipeline; study estimates were pooled using random-effects meta-analysis. Main Outcomes and Measures Gaussian mixture models (GMMs) were fitted to Centiloid values for each study. In studies with a bimodal distribution (per integrated completed likelihood), single cutoffs for positivity were set as mean plus 2 SDs of the lower gaussian component. Using GMMs, a double-cutoff approach defined a lower certainty range using a 90% posterior probability cutoff for assignment to the low (amyloid-negative) vs high (amyloid-positive) component. An alternative Centiloid cutoff was derived from maximizing the correspondence (Cohen κ) with the binary visual reads when available. Results This meta-analysis included cross-sectional amyloid PET scans acquired with 5 radiotracers from 49 227 participants across 53 studies from 15 countries (mean age, 71 years; 54% female, 62% cognitively impaired). The data-driven GMM approach identified a bimodal distribution in 51 studies (n = 48 786), resulting in a single cutoff for positivity of 18 Centiloids (95% CI,16-19; I 2 = 97%). The double-cutoff approach revealed high confidence for interpreting scans as negative when Centiloid values were lower than 11 (95% CI, 9-13; I 2 = 95%) and interpreting scans as positive if Centiloid values were higher than 26 (95% CI, 24-28; I 2 = 95%). In analyses of correspondence with binary (positive or negative) visual reads of amyloid PET scans (n = 35 045; 36 studies), Centiloids were highly predictive of visual positivity (Cohen κ, 0.86; 95% CI, 0.83-0.89; I 2 = 96%) with a cutoff of 27 Centiloids (95% CI, 24-30; I 2 = 80%). Conclusions and Relevance In this individual participant data meta-analysis, positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads). Findings from a double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use.
Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
A, Prera Vilaseca, Bilodeau, Philippe, Gakis, Georgios , Savransky, Andrea, Oliveira, Joao Mahler Ferreira, Nguyen, Linda, Hooshmand, Sam I., Satyanarayan, Sammita , Moseley, Carson E., Haley, Leah , Roy-Hewitson, Chantal, Marrodan, M, Casallas, Adriana, Manín, Analisa , Chen, H, Grzezulkowska, Aniela, Contentti, Edgar Carnero, Galleguillos, Lorna, Upchurch, Margaret, Jackson-Tarlton, Caitlin S. , Guo, Joanne Chu-Yueh, Fabian, Michelle, Caparó-Zamalloa, César, Paterno, R, Waubant, Emmanuelle, Boschetti, Laura Ordoñez, Correale, Jorge, Villa, Andrés M., Banwell, Brenda, Marignier, Romain, Pittock, Sean J., Greenberg, Benjamin , Bennett, Jeffrey L., Cho, Tracey, Clardy, Stacey, Solomon, Andrew J., Ja, Gelfand, Obeidat, Ahmed Z., Blackburn, Kyle, Tenembaum, Silvia , Chen, John J., Sotirchos, Elias S., Levy, Michael, Flanagan, Eoin P., Group, and The Americas MOGAD Treatment, Murillo, Fabian, Syc-Mazurzek, Stephanie B., Jiang, Mulan , Rezende, N, Wingerchuk, D M, Horsman, Susan E. , Bilodeau, Philippe‐Antoine , Bilodeau, Philippe A , Vilaseca, Andreu , Hooshmand, Sam , Moseley, Carson E. , Marrodán, Mariano , Vanegas, Adriana Casallas , Hoshina, Yoji , Contentti, Edgar Carnero , Galleguillos, Lorna , Virupakshaiah, Akash , Arrambide, Georgina , Caparó‐Zamalloa, César , Waubant, Emmanuelle L. , Ordóñez-Boschetti, Laura, Villa, Andres Maria , Marignier, Romain , Pittock, Sean J. , Bennett, Jeffrey L. , Cho, Tracey , Clardy, Stacey , Solomon, Andrew , Kister, Ilya , Zamvil, Scott S. , Gelfand, Jeffrey M. , Repovic, Pavle , Obeidat, Ahmed Zayed , Blackburn, Kyle , Chen, John J., Sotirchos, Elias S. , Levy, Michael , Flanagan, Eoin P. , Syc‐Mazurek, Stephanie B. , Cacciaguerra, Laura , Rezende, Nathane Braga da Silva, Wingerchuk, Dean M.

Mayo Clinic

JAMA Neurology | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2220 | PMID 42440328 Get It

Importance Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) lacks proven relapse-preventive therapies. While clinical trials are ongoing, safety data may be limited and approved drugs are costly. Studies of interleukin 6 receptor blocker (IL-6RB) in MOGAD are limited by small numbers and no comparative studies, contributing to low use. Objective To evaluate the impact of IL-6RB therapy on relapse rates in MOGAD and compare relapse frequency with intravenous immunoglobulin (IVIG). Design, Setting, and Participants This international, multicenter, retrospective cohort study (January 1, 2015, through December 31, 2025) included a historical IVIG-treated cohort of varying doses. The study took place across sites in North and South America (US, Canada, Mexico, Argentina, Brazil, Chile, Colombia, and Peru). Patients with MOGAD (n = 116, no excluded patients) who received at least 1 dose of an IL-6RB were included. These data were analyzed in January 2026. Exposures Tocilizumab or satralizumab. Main Outcomes and Measures Annualized relapse rate (ARR) during IL-6RB therapy, time to next relapse after treatment initiation, and adverse events. Outcomes were compared with the IVIG cohort using inverse probability of treatment weighting (IPTW) adjusted for age, sex, prior ARR, and concomitant therapies. Results A total of 116 patients with MOGAD (89% relapsing) receiving IL-6RB (tocilizumab, 104 [90%] and satralizumab, 12 [10%]) were included; overall, 60.3% were female, 39.7% were male, and 18% were younger than 18 years. The median (IQR) IL-6RB treatment follow-up was 1.4 (0.7-2.5) years and 23 relapses occurred during 241.8 person-years of IL-6RB therapy. The ARR decreased from 0.64 (95% CI, 0.58-0.70) for relapsing MOGAD before IL-6RB to 0.09 (95% CI, 0.06-0.14) during IL-6RB treatment (incidence rate ratio, 0.08; 95% CI, 0.04-0.16). Adverse events occurred in 58 patients (50%), most commonly mild infections, although 10 (9%) had severe infections. In the IVIG cohort (n = 59), 30 relapses occurred over 133.8 person-years (ARR, 0.22; 95% CI, 0.15-0.32). After IPTW, IL-6RB was associated with a lower hazard ratio (HR) than the group who underwent IVIG therapy less than 1 g/kg every 4 weeks (HR, 4.5; 95% CI, 2.0-9.8), with no significant difference vs the group who underwent IVIG 1 g/kg or more every 4 weeks (HR, 2.0; 95% CI, 0.8-4.5). Conclusions and Relevance In this multicenter observational cohort, IL-6RB use in MOGAD was associated with low relapse rates and a favorable safety profile, though severe infections occurred occasionally. Relapse rates were lower than the group who underwent IVIG less than 1 g/kg every 4 weeks but not significantly different from the group who underwent IVIG 1 g/kg or more every 4 weeks. This supports IL-6RB as a potential relapse-prevention therapy in MOGAD; the wide availability and relative affordability of tocilizumab may enable broad global use.
Assessing Equality of Touch to Guide Targeted Implementation of Post-induction Surface Disinfection Cleaning and Augmentation With Ultraviolet-C Irradiation
Dexter, Franklin, Koff, Matthew D. , Gibbons, Stephanie N., Hadder, Brent , Seering, Melinda , Wanta, Brendan T., Brindeiro, Carmen T., Dexter, Franklin , Loftus, Randy W. , Charnin, Jonathan E. , Seering, Melinda S , Gibbons, Stephanie, Brindeiro, Carmen T, Brown, Jeremiah R.

Mayo Clinic

A&A Practice | July 13, 2026 | Volume: 20 | Issue: 7 | Pages: e02245

10.1213/xaa.0000000000002245 | PMID 42439444 Get It

BACKGROUND: Improved cleaning in the anesthesia workspace is important for surgical site infection prevention. We sought to identify high-priority cleaning targets to guide post-induction surface disinfection and use of a triangular ultraviolet-C (UV-C) configuration involving placement of one emitter at the head and one on each side of the surgical bed. METHODS: The 20 sites most frequently touched by anesthesia practitioners, previously identified via video-based workflow analysis, were filtered to remove disposable (eg, stopcocks) and transient (eg, the patient bed) sites, leaving durable cleaning targets amenable to repeated surface disinfection and UV-C irradiation within and/or between cases. Inequality in the distribution of cleaning target touches was quantified using the Gini coefficient, and uncertainty was estimated using bootstrap resampling (10,000 iterations). We then assessed residual contamination after standard terminal cleaning across three operating rooms and 171 sites to evaluate the difficulty of cleaning high-touch surfaces and the efficacy of UV-C disinfection. Simulations using medical devices composed of materials representative of cleaning targets contaminated with high-level Clostridium difficile were conducted to evaluate generalizability to more resistant pathogens. RESULTS: There were 13 of 20 frequently touched sites that were considered durable cleaning targets. Touches were relatively equal among the 13 cleaning targets (Gini coefficient 0.16, 95% confidence interval [CI], 0.12–0.20). Cleaning targets included components of the anesthesia cart (first and second drawer handles); anesthesia machine (reservoir bag, circuit ventilator control, oxygen dial, vaporizer dial, adjustable pressure-limiting valve), monitoring equipment (screen buttons/knob, electrocardiogram leads); and room infrastructure (intravenous pole, operating room table and chair). Residual contamination after cleaning was identified at 4% (7/171) of sites, mostly (6/7) within the anesthesia workspace, involving the anesthesia cart (N = 2), machine (N = 3), and monitor (N = 1). Only one site outside of the anesthesia workspace, the circulating nurse’s mouse, had residual contamination. Triangular UV-C reduced mean (standard deviation [SD]) colony-forming units (CFU) from 60.47 (542.22) to 0.12 (1.08), achieving a 2.7-log reduction. Simulation with high-level C. difficile contamination demonstrated ≥3-log reductions on surfaces representative of high-touch sites, confirming applicability to resistant pathogens. CONCLUSIONS: Thirteen durable cleaning targets in the anesthesia workspace are largely equivalent in terms of risk of touch. They are amenable to UV-C augmentation of surface disinfection in the real-world clinical environment. These findings can guide targeted post-induction cleaning and use of triangular UV-C, particularly for surfaces with substantial contamination or resistant pathogens.
Community-informed development of an in-person forum to promote breast cancer screening and research preparedness in rural and low-socioeconomic status women
Sharma, Pravesh , Imsande, Kaylynn G., Vitriago, Anni, Seibel, Maria, Pritchett, Josh, Rudder, B. de, Tran, Linh T., Larson, Stephanie L., Flock, Carolyn, Murphy, Crystal, Asiedu, Gladys B. , Odedina, Folakemi T., Lynch, Brian, Haddad, Tufia C. , Pritchett, Joshua , Rudder, Bongi, Larson, Stephanie, Patten, Christi , Asiedu, Gladys B , Haddad, Tufia, Sharma, Pravesh , Imsande, Kaylynn G, Larson, Stephanie, Flock, Carolyn R., Murphy, Crystal, Patten, Christi A. , Odedina, Folakemi

Mayo Clinic

Journal of Clinical and Translational Science | July 13, 2026 | Volume: 10 | Issue: 1 | Pages: No page available

10.1017/cts.2026.10788 | PMID 42534402 Get It

Abstract Rural and low-socioeconomic status women face social determinants of health barriers leading to disproportionately low rates of breast cancer screening and markedly reduced participation in clinical trials. To address this gap, we developed the WeCARE (Women’s Engagement for Cancer Awareness, Resources, and Education) intervention using a community-engaged approach. This paper describes how Community Advisory Board feedback informed the development of Mayo Clinic Health System’s WeCARE intervention components. Their input was systematically analyzed using the Consolidated Framework for Implementation Research (CFIR 2.0) to identify determinants of acceptability, appropriateness, and feasibility and to guide actionable refinements to intervention content and delivery.
Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology
Kamran, Sophia C. , Borges, Monica, Michalski, Jeff M. , Lee, W. Robert , Sandler, Howard M. , Crook, Juanita , Pollack, Alan , Hurwitz, Mark , Valicenti, Richard K., Bruner, Deborah Watkins , Lukka, Himanshu, Jones, Christopher U. , Roach, Mack , Lawton, Colleen, PISANSKY, T, Spratt, Daniel, VAPIWALA, N, Miyamoto, David T. , Mouw, Kent, Vyfhuis, Melissa A.L. , Le, Quynh‐Thu , Willers, Henning , Franklin, Huang, Bahary, Jean-Paul , Helou, Joelle, Pugh, Stephanie L. , Wenzel, Jennifer , Michalski, Jeff M , Pisansky, Thomas M. , Efstathiou, Jason A , Miyamoto, David , Vyfhuis, Melissa , Le, Quynh-Thu , Van Allen, Eliezer M , Bahary, Jean-Paul , Wenzel, Jennifer , Tran, Phuoc T , Bruner, Deborah , Sandler, Howard M , Valicenti, Richard K., Lukka, Himanshu, Rosenthal, Seth A. , Spratt, Daniel E. , Vapiwala, Neha , Efstathiou, Jason A. , Helou, Joelle

Mayo Clinic

JCO Precision Oncology | July 8, 2026 | Volume: 10 | Issue: 7 | Pages: No page available

10.1200/po-26-00158 | PMID 42418740 Get It

PURPOSE Precision medicine has revolutionized oncology; however, tumor biomarkers are not reflective of the heterogeneous cancer population. We evaluated NRG Oncology prostate cancer (PCa) clinical trials for demographic differences among patients with optional biospecimen collection (BC) consent and biospecimen submission (BSub). METHODS Data from 19 NRG PCa clinical trials closed before 2015 were analyzed. Patients who consented to BC and completed BSub were evaluated by race, ethnicity, median income, area deprivation index (ADI; categorized as highest v lowest three quartiles), age at enrollment, site, and year of enrollment. T/chi-square tests were used for continuous/categorical variables, respectively, followed by logistic regression. RESULTS Of the 15,648 randomized patients eligible for BC, 11,796 (75%) had specimens submitted. In all, 4,598 (82.2%) of 5,597 eligible patients consented for optional BC in nine clinical trials with a separate BC consent process (consent rates by race/ethnicity: 74.1% Black, 72.8% Hispanic/Latino, 83.8% White). A smaller proportion of Black and Hispanic/Latino patients consented to optional BC compared with those who did not (12.1% v 19.5% Black, P < .0001; 3.5% v 5.8% Hispanic, P = .0006). In univariable logistic regression models, high ADI (more socioeconomic disadvantage) was associated with a decreased likelihood for optional BC consent (odds ratio [OR], 0.67 [95% CI, 0.55 to 0.82]; P = .02), but not a decreased likelihood for BSub (OR, 0.74 [95% CI, 0.53 to 1.04]; P = .08). Multivariable models demonstrated that Black/Hispanic/Latino patients were less likely to consent to optional BC, and Black patients were less likely to have BSub ( P < .05 for all). CONCLUSION White/non-Hispanic patients and those with less socioeconomic disadvantage were more likely to consent to optional BC, whereas Black patients were less likely to have BSub. Targeted solutions are needed to improve biorepository representation so that precision medicine approaches better reflect the cancer population.
Antisense Oligonucleotide Tofersen Distribution in the Central Nervous System of SOD1 -ALS Autopsy Tissue Donors
Sellon, Monica Thanawala, Roemer, Shanu F., Monine, Michael, Harris, Nicole , Bartlett, Dan, David, Eric, Xu, Shanqin, Jandreski, Luke , Malek, Sohail, Garafalo, Steve, Nestorov, Ivan , Ireland, Margaret D., Bowser, Robert , Korobeynikov, Vladislav, Ravits, John, Shaw, Pamela J., Highley, J. Robin, Ferguson, Toby A. , Fradette, Stephanie , Graham, Danielle , Sorenson, Eric J. , Oskarsson, Björn, Reichard, R. Ross , Dickson, DW, Paganoni, Sabrina, Oakley, Derek H., Frosch, Matthew P. , Miller, Timothy M. , Bucelli, Robert C., Perrin, Richard J., Plowey, Edward D., Guise, Amanda J. , Roemer, Shanu F. , Monine, Michael I. , Comfort, Nicole T. , Nestorov, Ivan, King, Andrew, Korben, Vlad A. , Ravits, John , Shaw, Pamela J. , Highley, J. Robin , Dickson, Dennis W. , Paganoni, Sabrina , Babu, Suma , Oakley, Derek H. , Bucelli, Robert C. , Perrin, Richard J. , Ly, Cindy V. , Plowey, Edward D.

Mayo Clinic

JAMA Neurology | July 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2195 | PMID 42406382 Get It

Importance Tofersen is a disease-modifying antisense oligonucleotide therapeutic for people living with SOD1 –amyotrophic lateral sclerosis ( SOD1 -ALS). Autopsy tissue donors have provided the first opportunity to study the distribution of intrathecally administered tofersen in human central nervous system tissues. Objectives To determine the tissue distribution of tofersen and to provide the first estimates of SOD1 reduction in human somatic motor systems tissues. Design, Setting, and Participants This was a cross-sectional autopsy tissue case series conducted between 2018 and 2026. Autopsies were performed at 3 US academic medical institutions. Tissue samples from 8 deceased patients who lived with SOD1 -ALS, participated in tofersen clinical trials (ClinicalTrials.gov Identifiers NCT02623699 [An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)] and NCT03070119 [Long-Term Evaluation of BIIB067 (Tofersen)]) or the Expanded Access Program, and whose families authorized autopsies were eligible for this study. All autopsy tissue donors known at the time of this study were included (none were excluded). Analyses were conducted between August 2020 and January 2026. Exposures Participants received multiple intrathecal 20- to 100-mg tofersen doses. Main Outcomes and Measures Tofersen tissue concentrations were measured using hybridization enzyme-linked immunosorbent assay (ELISA). SOD1 messenger RNA (mRNA) and protein reduction estimates, defined as percentage SOD1 levels in this study’s recently treated autopsy tissue donors compared to a cohort of samples from tofersen-naive SOD1 -ALS autopsy tissue donors, were measured using quantitative reverse transcription polymerase chain reaction (PCR) and ELISA. Histological localization of tofersen and SOD1 transcripts were studied using immunohistochemistry and in situ hybridization assays. Results In 8 tofersen-treated autopsy tissue donors (5 male and 3 female donors; age range, 42-66 years), spinal cord and motor cortical tissue tofersen concentrations strongly correlated with predictions based on individual dosing histories and a preclinical pharmacokinetic model. For 3 recently treated autopsy tissue donors, reductions in lumbar spinal cord tissue SOD1 mRNA and protein levels ranged from 45% to 84% despite not having been administered 1 to 2 scheduled doses before autopsy. Residual somatic motor neurons demonstrated tofersen transduction and low SOD1 mRNA probe hybridization. Misfolded SOD1 protein inclusions were detected in residual motor neurons of tofersen-naive SOD1- ALS tissue donor controls and tofersen-treated tissue donors. Meningeal and perivascular lymphocytic immune responses were observed in 5 recently treated tissue donors but were not apparent in tissue donors with remote final tofersen doses. Conclusions and Relevance This case series presents the first emerging autopsy tissue data confirming the predicted distribution of tofersen and robust SOD1 protein reduction in human somatic motor systems tissues.
Epiretinal membranes in multiple sclerosis: A window into glial pathobiology?
Chen, John J. , Syc-Mazurek, Stephanie B , Chen, John J , Syc‐Mazurek, Stephanie B.

Mayo Clinic

Multiple Sclerosis Journal | July 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/13524585261464504 | PMID 42405522 Get It

Patient Perspectives on an Autonomous Wheelchair Transport Pilot in a Tertiary Medical Center: A Cross-Sectional Survey
Hurt, Stephanie Decker, Bowman, Jon E., Schroeder, Darrell R. , Croghan, Ivana T. , Schroeder, Darrell , Croghan, Ivana T , Varayil, Jithinraj Edakkanambeth , Fischer, Karen M.

Mayo Clinic

Journal of Primary Care & Community Health | July 4, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/21501319261463381 | PMID 42400404 Get It

Objective To evaluate patient satisfaction with the experience of using an autonomous wheelchair to transport patients in a large outpatient clinical environment. Methods The autonomous wheelchair pilot was approved as a feasibility pilot by the institutional committees and deemed a quality improvement project by the Institutional Review Board (IRB). A total of 409 adult patients using an autonomous wheelchair at a large academic medical center who volunteered to complete a paper survey were included. The survey was administered immediately after autonomous wheelchair use, using a cross-sectional, anonymous survey, between 15 Oct 2025 and 14 Jan 2026. Of 409 completed surveys, six were excluded because participants did not identify their endpoint for stratification purposes. Descriptive analysis included frequencies and percentages of responses. Results No collisions or adverse events were observed during the pilot, and the system operated reliably within the predefined routes. Most survey respondents were first-time users (335/402 [83.3%]). A majority reported they would use the autonomous wheelchair again (341/395 [86.3%]) and would recommend it to others (364/397 [91.7%]). Overall, the experience was rated better than expected by 293 of 393 participants (74.6%). When given a choice, 271 of 379 respondents (71.5%) preferred the autonomous wheelchair over a staff-operated wheelchair. Conclusion These findings suggest that autonomous wheelchairs are feasible and acceptable to patients in a controlled outpatient setting and support continued piloting and prospective evaluation.
Association of a Polygenic Risk Score with Diagnosis and Outcomes in Idiopathic Pulmonary Fibrosis
Kalra, S. , Grilli, Christopher, Coombes, Brandon J. , Armasu, Sebastian M. , Upjohn, D, Egan, Jan B. , Chen, Qingwen , Tern, Courtney , Zhang, Chengyue, Rose, Jonathan A. , Putman, Rachel, McDermott, Greg, Hsieh, Yuli Lily , Bublitz, Michele L., Carmona, Eva M. , Klee, Eric W, Lazaridis, K, Peljto, Anna L. , Schwartz, D A, Silverman, Edwin K. , Olson, Janet, Walker, T, Zamora, Ana C., Zein, Joe , Ortega, V E, Cohort, Tapestry, McDermott, Gregory C , Kalra, Sean S , Grilli, Christopher B , Armasu, Sebastian , Upjohn, David P , Hsieh, Yuli L , Lasky-Su, Jessica , Silverman, Edwin K , Allen, Richard J , Walker, T'Nita, Wain, Louise V , Zamora, Ana, Zein, Joe G, Hunninghake, Gary M , Moll, Matthew , Cho, Michael H , Carmona, Eva M , McDermott, Gregory , Coombes, Brandon J , Putman, Rachel K. , Kn, Lazaridis, Lasky‐Su, Jessica , Dudbridge, Frank , Allen, Richard J. , Olson, JA, Hunninghake, Gary M. , Ali, Ahmad Hafiz , Sekulić, Aleksandar , Athreya, Arjun P. , Clermont, Blake J, N, Brittany, Burnap, Graddy, Courtney B., Cahn, Elliot, Klee, Eric W. , Sicotte, Hugues , Ekpoh, Idara U., Frank, Jacob A., Bruflat, Jamie K., Kemppainen, Jennifer L., Samadder, Jewel, Presutti, John J, Leitzke, Jon W, Lazaridis, Konstantinos N. , Tree, Kristine M, Jones, Leila A, Bandel, Lorelei A. , Karow, Mary E., Peterson, Melanie M., Bublitz, Michelle L. , Morales-Rosado, Joel, Erwin, Nate P., Larson, Nicholas B. , Olson, Rory, Vierkant, Robert A., Pignolo, Robert J. , Safgren, Stephanie, Bagaria, Sanjay P. , Tian, Shulan , Kaggal, Suneetha, Walker, T'Nita S., Wilson, Tammy A., McAllister, Tammy M., Tan-Arroyo, Jennifer, Luehrs, Tony, Ortega, Victor E. , Chen, Wenan , Cho, Michael H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrccm/aamag271 | PMID 42391602 Get It

Abstract Rationale Idiopathic Pulmonary Fibrosis (IPF) is characterized by chronic progressive pulmonary fibrosis and high mortality. Genetic markers, summarized into a polygenic risk score (PRS), associate with IPF in well-phenotyped research cohorts. Objectives To evaluate the performance of the PRS using real-world data from routinely captured electronic healthcare records. Methods We conducted an observational study evaluating the association of a PRS for IPF with electronic healthcare record diagnosis of IPF as well as lung transplant-free survival in four independent cohorts; the Mass General Brigham Biobank (MGBB), Mayo Clinic Biobank (MCBB), Mayo Clinic Tapestry Cohort (Tapestry), and U.K. Biobank (UKBB). We used multivariable logistic regression and multivariable Cox proportional hazards models adjusting for age, gender, and principal components of ancestry. The cohorts then underwent fixed and random effects meta-analysis. Measurements and Main Results Of 37,709; 44,195; 43,202; and 447,422 participants from MGBB, MCBB, Tapestry and UKBB respectively, 1,015 (2.7%) 2,879 (6.5%), 1,310 (3.0%), and 2,742 (0.6%) participants had an IPF diagnosis. Meta-analysis demonstrated a high-risk PRS associated with IPF diagnosis, OR 2.88 (95%CI 2.41-3.44) compared to all other individuals. A high-risk PRS also associated with the composite endpoint of mortality or lung transplant among those with an IPF diagnosis, HR 1.23(95%CI 1.11-1.35) compared to all other individuals. Conclusions A PRS can identify those at risk for an IPF diagnosis and mortality in biobank-scale data, which may have implications for clinical decisions. Further work is necessary to evaluate the utility of adding genetics in clinical settings.